Fresh Equities
CELLMID LIMITED

CELLMID LIMITED

ASX:CDY

Company Information

Cellmid Limited (CDY) is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lyramid, Kinera and Advangen, develops and markets in novative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. They operate through two business segment Midikine and Consumer health. Former Names Medical Therapies Limited (MTY) on 19/11/2009.

Type

Listed Company

GICS Sub-Industry

Biotechnology

Head Office

Suite 204, Level 2/55 Clarence St, Sydney NSW 2000, Australia

Biotechnology
Health Care

Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.



Fresh Equities

Copyright © 2018 Fresh Equities. All rights reserved.

ACN 619 657 028. CAR: 001267539 of AFSL: 471379.
Archive
Support
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by Fresh Equities Pty Ltd, its representatives or any other third party regardless of whether such security, product or service is referenced on this website.